On May 23, 2022, the Association for Accessible Medicines and its Biosimilars Council urged the Federal Trade Commission (FTC) to investigate the competitive impact of pharmacy benefit managers (PBMs) and their various abusive behaviors that undermine patient access to safe, affordable pharmaceutical care.
WASHINGTON, D.C.
This article first appeared in Chain Drug Review on January 5, 2021 as Pharmacy Outlook: Dan Leonard.
WASHINGTON, DC (June 18, 2020) — The Association for Accessible Medicines (AAM) welcomed U.S. Trade Representative Ambassador Robert Lighthizer’s commitment during his testimony yesterday before the House Ways and Means Committee that the free trade agreement currently being negotiated, including with the United Kingdom, will not contain a provision requiring 10-years of biologic exclusivity.
WASHINGTON DC (January 29, 2020) – “The Association for Accessible Medicines applauds President Trump’s signing of the U.S.-Mexico-Canada Agreement, the new gold standard for free trade agreements. Not only will patients have greater access to affordable medicines as a result of the USMCA, but America’s patients can be assured that this agreement promotes competition, access and innovation, the three building blocks of America’s globally leading pharmaceutical industry.
WASHINGTON DC (January 16, 2020) – “The Association for Accessible Medicines strongly endorses the Senate’s bipartisan passage of the U.S.-Mexico-Canada Agreement. For the first time in a trade agreement, a balance between support for innovation and access to affordable medicines has been reached. This balance will not only allow the growth of U.S. brand, generic and biosimilar pharmaceutical companies, but will also support increased access to competitively priced medicines in the United States.
WASHINGTON DC (December 19, 2019) – “The Association for Accessible Medicines applauds the House of Representatives' overwhelming bipartisan passage of the U.S.-Mexico-Canada Agreement. The vote was 385 to 41.
AAM is pleased that Congress and the Administration have made changes to USMCA that support open markets, greater competition and improved cost savings for patients and the three health care systems. The revised USMCA trade agreement creates greater opportunities for patients in Mexico, Canada and the United States to access less expensive medicines and promotes a competitive pharmaceutical market across the three countries.
Read the AAM press release: https://accessiblemeds.org/resources/press-releases/usmca-trade-agreement-victory-americas-patients
WASHINGTON DC (December 10, 2019) – Today’s agreement reached by the Congressional Trade Working Group and the Trump administration represents a victory for patients.
The revised text creates greater opportunities for patients in Mexico, Canada and the United States to access less expensive medicines and promotes a competitive pharmaceutical market across the three countries. The improved pharmaceutical provisions create the balance between access to medicines and support for innovation that was included in bipartisan 2015 Trade Promotion Authority legislation.
Brand-name drug companies claim that without USMCA, there's no market for biologics in Mexico. But, the world's largest pharmaceutical companies launched their top-selling biologics in Mexico. Learn more in this infographic:
